Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease

Transplant International

Volumn 30, Issue 3, 2017, Pages 243-255

  Herzer, Kerstin ^a   Welzel, Tania M ^b   Spengler, Ulrich ^c   Hinrichsen, Holger ^d   Klinker, Hartwig ^e   Berg, Thomas ^f   Ferenci, Peter ^g   Peck Radosavljevic, Markus ^g,h   Inderson, Akin ⁱ   Zhao, Yue ^j   Jimenez Exposito, Maria Jesus ^j   Zeuzem, Stefan ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Gastroenterologisch Hepatologisches Zentrum   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h Klagenfurt am Wörthersee Hospital   (Austria)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Decompensated; fibrosing cholestatic hepatitis; HCV therapy; liver transplant

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DACLATASVIR; HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CHILD PUGH SCORE; CHOLESTATIC HEPATITIS; CREATININE CLEARANCE; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; LACTIC ACIDOSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PANCYTOPENIA; PATIENT HISTORY OF LIVER TRANSPLANTATION; RECURRENT INFECTION; SEBORRHEIC DERMATITIS; SIDE EFFECT; SLEEP DISORDER; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; ADVERSE EFFECTS; COHORT ANALYSIS; COMBINATION DRUG THERAPY; COMPLICATION; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; LIVER TRANSPLANTATION; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 85014041014     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12910     Document Type: Article

References (32)

1. Kim WR, Lake JR, Smith JM, et al. Liver. Am J Transplant 2016; 16(Suppl. 2): 69.
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593.
3. Beinhardt S, Peck-Radosavljevic M, Hofer H, et al. Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Hepatitis C Virus and Liver Transplantation: Where do we Stand?. Transpl Int. 2015; 28: 1011.
4. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228.
5. Bizollon T, Pradat P, Mabrut JY, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909.
6. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389.
7. Coilly A, Roche B, Duclos-Vallee JC, Samuel D. News and challenges in the treatment of hepatitis C in liver transplantation. Liver Int 2016; 36(Suppl. 1): 34.
8. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649.
9. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375.
10. Kwo PY. Direct acting antiviral therapy after liver transplantation. Curr Opin Gastroenterol 2016; 32: 152.
11. Crittenden NE, Buchanan LA, Pinkston CM, et al. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation. Liver Transpl 2016; 22: 635.
12. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108.
13. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology 2016; 63: 1493.
14. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16: 685.
15. Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant 2015; 20: 235.
16. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013; 3: 514.
17. Sofia MJ, Bao D, Chang W, et al. Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202.
18. Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig 2015; 35: 281.
19. Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 2015; 54: 677.
20. Coilly A, Fougerou-Leurent C, de Ledinghen V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence – the ANRS CUPILT study. J Hepatol 2016; 65: 711.
21. Kwo P, Fried MW, Reddy R, et al. Daclatasvir and sofosbuvir in patients with recurrent HCV following liver transplantation with advanced fibrosis or cirrhosis: United States multicenter treatment protocol [Abstract]. Hepatology 2015; 62(Suppl. S1): 321A.
22. Leroy V, Hezode C, Metivier S, et al. Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV infection and decompensated cirrhosis: interim analysis of a French multicentre compassionate use programme [Abstract]. J Hepatol 2016; 64(Suppl. 2): S829.
23. Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologic response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016; doi: 10.1136/gutjnl-2016-312444. [Epub ahead of print].
24. US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v. 1.0 Updated August 2009). http://rsctech-rescom/safetyandpharmacovigilance/gradingtablesaspx. Accessed 31 January 2012.
25. Leroy V, Dumortier J, Coilly A, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol 2015; 13: 1993.
26. Brown RJ, Fried MW, Reddy K, et al. Daclatasvir and sofosbuvir for patients with decompensated cirrhosis or post-liver transplant HCV recurrence and advanced fibrosis or cirrhosis: United States multicentre treatment protocol [Abstract]. J Hepatol 2016; 64(Suppl. 2): S814.
27. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016; 63: 1430.
28. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127.
29. Beinhardt S, Al Zoairy R, Ferenci P, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and post kidney transplantation setting. Transpl Int 2016; 29: 999.
30. Gilead Sciences Inc. Sovaldi (Sofosbuvir) US Prescribing Information, August 2015.
31. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents – a potentially lethal cocktail. Hepatology 2011; 54: 3.
32. Saab S, Rheem J, Jimenez M, et al. Curing hepatitis C in liver transplant recipients is associated with changes in immunosuppressant use. J Clin Transl Hepatol 2016; 4: 32.